Critical review of cancer risk associated with angiotensin receptor blocker therapy
The role of drugs in new cancer occurrence and cancer-related death is a major concern. Recently, a meta-analysis raised the possibility that angiotensin receptor blockers (ARBs) might have an adverse effect on patients. This generated a significant debate until the publication of two further meta-a...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2011
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253767/ |
| id |
pubmed-3253767 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-32537672012-01-12 Critical review of cancer risk associated with angiotensin receptor blocker therapy Wuerzner, Grégoire Burnier, Michel Waeber, Bernard Review The role of drugs in new cancer occurrence and cancer-related death is a major concern. Recently, a meta-analysis raised the possibility that angiotensin receptor blockers (ARBs) might have an adverse effect on patients. This generated a significant debate until the publication of two further meta-analyses, neither of which demonstrated an increased risk of new cancer occurrence or cancer-related death with the use of ARBs in patients with hypertension, heart failure, and/or nephropathy. This illustrates that the results of meta-analyses should be interpreted cautiously and critically as bias, such as selection bias, might lead to erroneous conclusions. Overall, the bulk of evidence today indicates that ARBs are not associated with increased cancer risk. Dove Medical Press 2011 2011-12-12 /pmc/articles/PMC3253767/ /pubmed/22241948 http://dx.doi.org/10.2147/VHRM.S13552 Text en © 2011 Wuerzner et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Wuerzner, Grégoire Burnier, Michel Waeber, Bernard |
| spellingShingle |
Wuerzner, Grégoire Burnier, Michel Waeber, Bernard Critical review of cancer risk associated with angiotensin receptor blocker therapy |
| author_facet |
Wuerzner, Grégoire Burnier, Michel Waeber, Bernard |
| author_sort |
Wuerzner, Grégoire |
| title |
Critical review of cancer risk associated with angiotensin receptor blocker therapy |
| title_short |
Critical review of cancer risk associated with angiotensin receptor blocker therapy |
| title_full |
Critical review of cancer risk associated with angiotensin receptor blocker therapy |
| title_fullStr |
Critical review of cancer risk associated with angiotensin receptor blocker therapy |
| title_full_unstemmed |
Critical review of cancer risk associated with angiotensin receptor blocker therapy |
| title_sort |
critical review of cancer risk associated with angiotensin receptor blocker therapy |
| description |
The role of drugs in new cancer occurrence and cancer-related death is a major concern. Recently, a meta-analysis raised the possibility that angiotensin receptor blockers (ARBs) might have an adverse effect on patients. This generated a significant debate until the publication of two further meta-analyses, neither of which demonstrated an increased risk of new cancer occurrence or cancer-related death with the use of ARBs in patients with hypertension, heart failure, and/or nephropathy. This illustrates that the results of meta-analyses should be interpreted cautiously and critically as bias, such as selection bias, might lead to erroneous conclusions. Overall, the bulk of evidence today indicates that ARBs are not associated with increased cancer risk. |
| publisher |
Dove Medical Press |
| publishDate |
2011 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253767/ |
| _version_ |
1611498710175318016 |